Cipan has a long tradition in the manufacture of antibiotics through fermentation and chemical synthesis and has been able to develop and maintain long-standing relationships with its clients, most of them located in the USA and in EU during its over 50 years activity.
Tetracyclines were the first anti-infectives manufactured at Cipan and still today are its main source of revenue, which comes both from the manufacturing and sales of our portfolio Tetracyclines and from the “contract development and manufacturing” of novel Tetracyclines which we are manufacturing exclusively to our innovation (as opposed to generics) based customers.
Building on that knowledge, our vision is to develop our business based on our biotech and chemical synthesis know-how taken side-by-side and magnified through our state-of-the-art multipurpose pilot and industrial facilities; strong engineering and regulatory capabilities and strong project management culture.
There is a wealth of resources at Cipan comprising people, facilities and equipment, regulatory expertise, analytical development and an engineering and project management culture that can be leveraged and brought to the service of prospective clients who are looking to develop their products from the grams scale into the kg, 100kg’s and 1000 kg’s scale.
Cipan’s chemical synthesis facility has a total reactor volume of 640 m3. The industrial fermentation unit has a total volume of about 860 m3, which makes Cipan’s fermentation facility one of the largest of its kind in Europe.
